New Blinded RCT to Assess Efficacy of Paresthesia-Free Spinal Cord Stimulation
A new blinded, multi-centre RCT will evaluate the efficacy of paresthesia-free spinal cord stimulation (PF-SCS) against placebo.
Phase III
Neurology / Pain Management
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
Successful outcomes could position PF-SCS as a leading treatment for refractory neuropathic pain, influencing market strategies for pain management products.
Why it matters
The ongoing RCT for paresthesia-free spinal cord stimulation (PF-SCS) is critical as it addresses previous methodological flaws, potentially validating PF-SCS as a leading treatment for refractory neuropathic pain. Positive trial outcomes could significantly influence market dynamics and competitive positioning in pain management therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results of the trial and any subsequent changes in clinical guidelines or competitive product positioning.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.